Skip to main content

Neurocrine Bioscienc(NBIX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low129.01
Day High131.05
Open:129.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Neurocrine Bioscienc

Select a category then submit the form to load news
Tipranks
Neurocrine (NBIX) Receives a Buy from RBC Capital
Motley Fool
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
Motley Fool
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
Motley Fool
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
Motley Fool
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale
Motley Fool
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider
Tipranks
Neurocrine (NBIX) Gets a Buy from Guggenheim
Tipranks
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Neurocrine (NBIX) and Dexcom (DXCM)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Dexcom (DXCM) and Icon (ICLR)
Tipranks
Neurocrine Biosciences Earnings Call Highlights Growth Momentum
Tipranks
Neurocrine (NBIX) Receives a Buy from Jefferies
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: CareDx (CDNA), Neurocrine (NBIX) and Viking Therapeutics (VKTX)
Tipranks
Wedbush Remains a Buy on Neurocrine (NBIX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC) and Neurocrine (NBIX)
Tipranks
RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX)
Tipranks
Stifel Nicolaus Keeps Their Buy Rating on Neurocrine (NBIX)
Motley Fool
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript
Tipranks
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Cardinal Health (CAH)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK)
Tipranks
Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Neurocrine (NBIX)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Concentra Group Holdings Parent, Inc. (CON), Neurocrine (NBIX)
Tipranks
Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (APGE) and Neurocrine (NBIX)
Tipranks
UBS Reaffirms Their Buy Rating on Neurocrine (NBIX)
Tipranks
Piper Sandler Keeps Their Buy Rating on Neurocrine (NBIX)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)
Tipranks
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Medline, Inc. Class A (MDLN)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA)
Tipranks
Neurocrine (NBIX) Receives a Buy from Canaccord Genuity
Tipranks
Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 2a Clinical Study
Tipranks
Neurocrine Biosciences Launches Phase 2 Trial for Bipolar I Disorder Treatment

Profile

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.